Navigation Links
Rigel to Host Conference Call to Discuss Phase 2 Study Results of R788 in Lymphoma Presented at ASH
Date:12/3/2008

SOUTH SAN FRANCISCO, Calif., Dec. 3 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that members of Rigel's senior management team will host a conference call with simultaneous webcast on Sunday, December 7, 2008, at 4:00 p.m. PST, to discuss the results of Rigel's Phase 2 clinical trial of R788, an oral Syk kinase inhibitor, in patients with B-cell non-Hodgkin's lymphomas.

Conference Call and Webcast Information

To access the live call, please dial 800-561-2693 (domestic) or 617-614-3523 (international) 10 minutes prior to the start time and use the passcode 36883961. A replay of the call will be available, in webcast and podcast formats, at approximately 6:00 p.m. PST on December 7, 2008 through December 14, 2008. To access the replay, please dial 888-286-8010 (domestic) or 617-801-6888 (international) and use the passcode 47095093. The conference call will also be webcast live and can be accessed from Rigel's website at http://www.rigel.com. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software downloads that may be necessary.

In addition, Rigel will be participating in a plenary session during the 50th Annual American Society of Hematology (ASH) Meeting in San Francisco, California from December 6-9, 2008.

ASH Presentation Details

Plenary session: Sunday, December 7, 2008 - 2:40 p.m. PST

Title: 3 - Fostamatinib Disodium (FosD), An Oral Inhibitor of Syk, Is Well-Tolerated and Has Significant Clinical Activity in Diffuse Large B-Cell Lymphoma (DLBCL) and Chronic Lymphoctytic Leukemia (SLL/CLL)

Location: Halls B and C (Moscone Center)

About Rigel (http://www.rigel.com)

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases and cancer, as well as viral and metabolic diseases. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. Rigel has product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia and asthma, as well as in cancer.

     Contact: Raul Rodriguez
     Phone: 650.624.1302
     Email: invrel@rigel.com

     Media Contact: Susan C. Rogers, Alchemy Consulting, Inc.
     Phone: 650.430.3777
     Email: susan@alchemyemail.com

'/>"/>
SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Rigel to Present at the 2008 Credit Suisse Healthcare Conference
2. Rigel Announces Third Quarter 2008 Financial Results and Clinical Update
3. Rigel to Host Update Conference Call
4. Rigel Announces Fourth Quarter and Year End 2007 Financial Results
5. Rigel to Present at BIO CEO & Investor Conference
6. Rigel Announces Pricing of Public Offering of Common Stock
7. Rigel to Present Research Programs at Scientific Conferences
8. Rigel to Present at BIO Investor Forum 2007
9. Abaxis, Inc. to Present at the RBC Capital Markets 2008 Healthcare Conference
10. Medarex to Present at the RBC Capital Markets Healthcare Conference
11. Bionovo to Present at the Piper Jaffray Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... genomics analysis platform specifically designed for life science researchers to analyze and ... researcher Rosalind Franklin, who made a major contribution to the discovery of ...
(Date:10/11/2017)... ... ... wash is a basic first aid supply for any work environment, but most personal eye ... first if a dangerous substance enters both eyes? It’s one less decision, and likely quicker ... eye piece. , “Whether its dirt and debris, or an acid or alkali, getting anything ...
(Date:10/11/2017)... INDIANAPOLIS , Oct. 11, 2017  VMS BioMarketing, a ... of a nationwide oncology Clinical Nurse Educator (CNE) network, which ... growing need for communication among health care professionals to enhance ... physicians, nurses, office staff, and other health care professionals to ... for breast cancer. ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... and pregnancy rates in frozen and fresh in vitro fertilization (IVF) ... maternal age to IVF success. , After comparing the results from the fresh ...
Breaking Biology Technology:
(Date:10/4/2017)... Oct. 4, 2017  GCE Solutions, a global clinical research organization ... document anonymization solution on October 4, 2017. Shadow is designed to ... comply with policy 0070 of the European Medicines Agency (EMA) in ... ... ...
(Date:6/30/2017)... , June 30, 2017 Today, ... developer and supplier of face and eye tracking ... Featured Product provider program. "Artificial ... innovative way to monitor a driver,s attentiveness levels ... from being able to detect fatigue and prevent ...
(Date:5/16/2017)... May 16, 2017  Veratad Technologies, LLC ( www.veratad.com ... age and identity verification solutions, announced today they will ... 2017, May 15 thru May 17, 2017, in ... International Trade Center. Identity impacts the ... in today,s quickly evolving digital world, defining identity is ...
Breaking Biology News(10 mins):